Search company, investor...

Barrier Therapeutics

tiefel.com

Founded Year

2001

Stage

Acquired | Acquired

Total Raised

$78.15M

Valuation

$0000 

Revenue

$0000 

About Barrier Therapeutics

Barrier Therapeutics is a specialty pharmaceutical company focused on development and commercialization of dermatology drugs

Headquarters Location

600 College Road East Suite 3200

Princeton, New Jersey, 08540,

United States

609-945-1200

Missing: Barrier Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Barrier Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Barrier Therapeutics Patents

Barrier Therapeutics has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/21/2013

10/6/2015

Piperazines, Dosage forms, Amines, Drug delivery devices, Pharmacokinetics

Grant

Application Date

6/21/2013

Grant Date

10/6/2015

Title

Related Topics

Piperazines, Dosage forms, Amines, Drug delivery devices, Pharmacokinetics

Status

Grant

Latest Barrier Therapeutics News

Recro Pharma Appoints Scott Rizzo as General Manager

Jul 20, 2015

07/20/2015 | 04:02pm US/Eastern (You can enter multiple email addresses separated by commas) Message : *Required fields MALVERN, Pa., July 20, 2015 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of acute post operative pain, today announced the appointment of Scott Rizzo as General Manager of the Company's contract manufacturing facility located in Gainesville, Georgia. "Scott brings 25 years of experience and a seasoned manufacturing background to Recro Pharma at an important and exciting time for the Company," said Gerri Henwood, Recro Pharma's President and Chief Executive Officer. "He has a proven track record in managing, growing and developing product operations, including manufacturing and distribution. Recro's Gainesville facility generates important cash flow for future manufacturing and product opportunities and we believe Scott's contributions will be invaluable as we work to maximize these opportunities. " Mr. Rizzo joins Recro Pharma from J. Knipper where he served as General Manager. Prior to J. Knipper, he was employed by Welmedix Consumer Healthcare where he served as Vice President, Manufacturing, Supply Chain and Quality Control. Prior to Welmedix, Mr. Rizzo held a number of senior consulting positions in Manufacturing and Supply Chain after he served as Vice President and Global Head of Supply Chain Operations at Barrier Therapeutics. In this role, he was responsible for guiding the supply chain and trade group at Barrier through multiple global product launches and life-cycle line extensions, all while mitigating the risk and cost of work in process and finished goods. Mr. Rizzo led cross-functional teams to improve speed to market and balance global inventory models all under a strict GMP environment. Prior to Barrier Therapeutics, Mr. Rizzo served as Director of North American Supply Chain for Hoffmann-La Roche. Prior to that, he was a consultant for Coopers & Lybrand and PriceWaterhouseCoopers, LLP where he led multiple successful engagements at top tier pharmaceutical companies and directed value chain initiatives. Mr. Rizzo is a graduate of Pennsylvania State University where he received both his Masters in Business Administration and his Masters of Manufacturing Management. He is a member of the Rutgers University Graduate Center for Supply Chain Studies and is on the Alumni Advisory Board for Pennsylvania State University. Inducement Equity Award In connection with the hiring of Mr. Rizzo, Recro Pharma's Compensation Committee approved a grant to Mr. Rizzo of a stock option to purchase 30,000 shares of Recro Pharma's common stock. The option was granted pursuant to the NASDAQ inducement grant exception as a component of Mr. Rizzo's employment compensation, and was granted as an inducement material to Mr. Rizzo's acceptance of employment with Recro Pharma in accordance with NASDAQ Listing Rule 5635(c)(4). The option will have an exercise price equal to the closing price of Recro Pharma's common stock on Monday, July 20, 2015. The option has a ten year term and vests over four years, with 25% of the original number of shares vesting on July 20, 2016 and the remaining 75% of the original number of shares vesting in equal monthly installments over the three years thereafter, subject to Mr. Rizzo's continued service with Recro Pharma through the applicable vesting dates. About Recro Pharma, Inc. Recro Pharma is a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of acute post operative pain. Recro Pharma is currently developing IV/IM meloxicam, a proprietary, Phase III-ready, long-acting preferential COX-2 inhibitor, and Dex-IN, a proprietary intranasal formulation of dexmedetomidine that has completed Phase II clinical trials, for the treatment of acute post operative pain. As Recro Pharma's product candidates are not in the opioid class of drugs, the Company believes its candidates would avoid many of the side effects associated with commonly prescribed opioid therapeutics, such as addiction, constipation and respiratory distress, while maintaining analgesic effect. Recro Pharma also owns and operates an 87,000 square foot, DEA-licensed facility that manufactures five commercial products and receives royalties associated with the sales of these products. Cautionary Statement Regarding Forward Looking Statements This press release contains forward-looking statements that involve risks and uncertainties. Such forward-looking statements reflect Recro Pharma's expectations about its future performance and opportunities that involve substantial risks and uncertainties. When used herein, the words "anticipate," "believe," "estimate," "upcoming," "plan," "target", "intend" and "expect" and similar expressions, as they relate to Recro Pharma or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information available to Recro Pharma as of the date of this press release and are subject to a number of risks, uncertainties, and other factors that could cause Recro Pharma's performance to differ materially from those expressed in, or implied by, these forward-looking statements. Recro Pharma assumes no obligation to update any such forward-looking statements. Factors that could cause Recro Pharma's actual performance to materially differ from those expressed in the forward-looking statements set forth in this press release include, without limitation: results and timing of the clinical trials of IV/IM meloxicam and Dex-IN; the ability to obtain and maintain regulatory approval of IV/IM meloxicam and Dex-IN, and the labeling under any such approval; regulatory developments in the United States and foreign countries; the Company's ability to raise future financing for continued development; the performance of third-party suppliers and manufacturers; the Company's ability to obtain, maintain and successfully enforce adequate patent and other intellectual property protection; the successful commercialization of IV/IM meloxicam and Dex-IN. In addition, the forward-looking statements in this press release should be considered together with the risks and uncertainties that may affect Recro Pharma's business and future results included in Recro Pharma's filings with the Securities and Exchange Commission at www.sec.gov . Recro Pharma assumes no obligation to update any such forward looking statements. CONTACT: Recro Pharma, Inc. Charles T. Garner Chief Financial Officer (484) 395-2425 Media and Investors: Argot Partners Susan Kim (212) 600-1902 susan@argotpartners.com © GlobeNewswire 2015 Latest news on RECRO PHARMA INC 04:02p

Barrier Therapeutics Frequently Asked Questions (FAQ)

  • When was Barrier Therapeutics founded?

    Barrier Therapeutics was founded in 2001.

  • Where is Barrier Therapeutics's headquarters?

    Barrier Therapeutics's headquarters is located at 600 College Road East, Princeton.

  • What is Barrier Therapeutics's latest funding round?

    Barrier Therapeutics's latest funding round is Acquired.

  • How much did Barrier Therapeutics raise?

    Barrier Therapeutics raised a total of $78.15M.

  • Who are the investors of Barrier Therapeutics?

    Investors of Barrier Therapeutics include Stiefel Laboratories, Aisling Capital, KBC Private Equity, Gemma Frisius Fonds, Panorama Capital and 8 more.

  • Who are Barrier Therapeutics's competitors?

    Competitors of Barrier Therapeutics include Neos Therapeutics, Lead Pharma, Charleston Laboratories, Prosonix, Ikaria, Revance Therapeutics, SkinMedica, Nanomed Pharmaceuticals, ZARS, Sirion Holdings and 12 more.

Compare Barrier Therapeutics to Competitors

S
Sirion Holdings

Sirion Holdings is a specialty pharmaceutical company focused on ophthamology drugs

A
Axcan

Axcan is a specialty pharmaceutical company focused on the development and commercialization of drugs for diseases involving the digestive system.

I
Ikano Therapeutics

Ikano Therapeutics is a specialty pharmaceutical company focused on developing nasally delivered pharmaceutical products with a particular focus on drugs treating pain and disorders related to the central nervous system.

T
Tequesta Marine Biosciences

Tequesta Marine Biosciences is a specialty pharmaceutical firm that develops small molecule therepeutic drugs for inflammatory conditions.

U
Urigen Pharmacueticals

Urigen specializes in the design and commercialization of innovative products for patients with urological ailments. The company develops products for amelioration of Painful Bladder Syndrome (PBS), Urethritis, Nocturia and Over Active Bladder (OAB).

Phico Therapeutics Logo
Phico Therapeutics

Phico Therapeutics is developing SASPject PT3.8, an antibacterial therapy for the systemic treatment of patients with serious Pseudomonas aeruginosa (P. aeruginosa) infections, which have a high mortality rate.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.